KIT and Miyoshi myopathy: A recent clinical trial of Dovitinib, a multikinase inhibitor with activity against FLT3/c-Kit, FGFR1/3 and VEGFR1-4 kinases, in patients with relapsed or refractory MM showed marginal efficacy in subjects with or without FGFR3 mutations [49].